How to Advance Cell & Gene Therapies with an Innovative, Flexible Approach

Today’s health industry is leveraging new, cutting-edge Cell & Gene Therapies (CGTs) to address a variety of medical illnesses and conditions that presently have no other treatments (e.g., gene therapies and CAR-T cell approaches to fight many types of cancer). Most CGT challenges relate to scalability and manufacturability. The circular CGT supply chain, with its highly personalized and novel therapies, is complex and variable. It requires strict collaboration among R&D, CMOs/CDMOs and hospitals. Most importantly, CGT treatments are “Live Drugs” incorporating ex vivo, in culture and in vivo therapies. This talk will cover the critical, end-to-end manufacturing analytics, laboratory informatics, and process performance reporting solutions required to drive innovation, reduce costs and accelerate Cell & Gene Therapies to patients.

 

Learning Objectives